Science Explorer Back to mapMap
Discussion
Institution · Indiana Cancer Consortium

Most cited papers from Indiana Cancer Consortium

Indiana Cancer Consortium

What are the most cited papers from Indiana Cancer Consortium?

The most cited paper from Indiana Cancer Consortium is "Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer" (Kathy D. Miller, Molin Wang, Julie R. Gralow et al., 2007), with 3,085 citations. Next come "Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings" (1,205) and "DESI 2024 VI: cosmological constraints from the measurements of baryon acoustic oscillations" (1,100).

Showing 50 of 60 papers. Every paper with more than 170 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer Kathy D. Miller, Molin Wang, Julie R. Gralow et al. · New England Journal of Medicine Open access 26 Dec 2007 3,085
2 Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings Lisa Sanderson Cox, Stephen T. Tiffany, Arden G. Christen · Nicotine & Tobacco Research Feb 2001 1,205
3 DESI 2024 VI: cosmological constraints from the measurements of baryon acoustic oscillations Adrian Gutierrez Adame et al. · Journal of Cosmology and Astroparticle Physics Open access201 authors Feb 2025 1,100
4 Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab Frank A. Scappaticci, Jamey R. Skillings, Scott N. Holden et al. · JNCI Journal of the National Cancer Institute Open access 8 Aug 2007 938
5 Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results Alexander M. Lesokhin et al. · Nature Medicine Open access 15 Aug 2023 636
6 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients Fausto Roila, Alex Molassiotis, Jørn Herrstedt et al. · Annals of Oncology Open access Sep 2016 584
7 Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study Kimberly Blackwell, Harold J. Burstein, Anna Maria Storniolo et al. · Journal of Clinical Oncology 12 Jun 2012 553
8 Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer Phil A. Hart, Melena D. Bellin, Dana K. Andersen et al. · ˜The œLancet. Gastroenterology & hepatology Open access 12 Oct 2016 551
9 Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies Cathy E. Elks et al. · Nature Genetics ReviewOpen access174 authors 21 Nov 2010 514
10 Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma Toni K. Choueiri et al. · Journal of Clinical Oncology Open access 4 Dec 2012 465
11 PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability Ana Beatriz Gonçalves da Silva, José Andrés Yunes, Bruno A. Cardoso et al. · Journal of Clinical Investigation Open access 15 Oct 2008 447
12 A unified multiwavelength model of galaxy formation Cedric G. Lacey, C. M. Baugh, Carlos Silvestre Frenk et al. · Monthly Notices of the Royal Astronomical Society Open access Aug 2016 429
13 Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody Neil Howard Segal, Theodore F. Logan, Frank Stephen Hodi et al. · Clinical Cancer Research Open access 18 Oct 2016 425
14 A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer Xianyin Lai, Mu Wang, Samantha Deitz McElyea et al. · Cancer Letters Open access 21 Feb 2017 396
15 Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers Johann Sebastian De Bono, Ramesh K. Ramanathan, Lida A. Mina et al. · Cancer Discovery Open access 27 Feb 2017 391
16 Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer N. Lynn Henry, Faouzi Azzouz, Zereunesay Desta et al. · Journal of Clinical Oncology Open access 14 Feb 2012 390
17 The Integrated Genomic Landscape of Thymic Epithelial Tumors Milan Radovich et al. · Cancer Cell Open access188 authors Feb 2018 389
18 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer Helen Lee, Anthony Frank Shields, Barry Alan Siegel et al. · Clinical Cancer Research Open access 15 Mar 2017 386
19 Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma Ashley R. Orillion, Ayumi Hashimoto, Nur P. Damayanti et al. · Clinical Cancer Research Open access 11 Jul 2017 375
20 MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways Xi Sheng Rao, Gianpiero Di Leva, Maggie Li et al. · Oncogene Open access 8 Nov 2010 344
21 Activation of the hedgehog-signaling pathway in human cancer and the clinical implications Ling Yang, Guorui Xie, Qianwen Fan et al. · Oncogene 23 Nov 2009 340
22 Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial Jeffrey S. Weber, Geoff Gibney, Ryan Joseph Sullivan et al. · The Lancet Oncology Open access 5 Jun 2016 338
23 Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer Sunil R. Hingorani, William Proctor Harris, Joseph Thaddeus Beck et al. · Clinical Cancer Research Open access 26 Jan 2016 330
24 Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma Toshihiko Doi, Sarina Anne Piha-Paul, Shadia Ibrahim Jalal et al. · Journal of Clinical Oncology Open access 8 Nov 2017 326
25 Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States Lori S. Muffly et al. · Blood Open access 3 Jul 2017 298
26 Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients Anne Auperin, Cecile Le Pechoux, Jean‐Pierre Pignon et al. · Annals of Oncology ReviewOpen access 24 Feb 2006 295
27 American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors Timothy D. Gilligan, Jerome Seidenfeld, Ethan Basch et al. · Journal of Clinical Oncology 8 Jun 2010 295
28 Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer Robert J. Gray, Suman Bhattacharya, Christopher Bowden et al. · Journal of Clinical Oncology Open access Sep 2009 295
29 Cell Cycle-Related Changes in Repopulating Capacity of Human Mobilized Peripheral Blood CD34+ Cells in Non-Obese Diabetic/Severe Combined Immune-Deficient Mice André Gothot, Johannes C.M. van der Loo, D. Wade Clapp et al. · Blood Open access 15 Oct 1998 289
30 Quantitation of Doxorubicin Uptake, Efflux, and Modulation of Multidrug Resistance (MDR) in MDR Human Cancer Cells Fei Shen, Shaoyou Chu, Aimee K. Bence et al. · Journal of Pharmacology and Experimental Therapeutics 19 Oct 2007 264
31 Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial Paul Edward Goss et al. · Journal of Clinical Oncology Open access 28 Jan 2013 261
32 DESI 2024 IV: Baryon Acoustic Oscillations from the Lyman alpha forest Adrian Gutierrez Adame et al. · Journal of Cosmology and Astroparticle Physics Open access198 authors 2025 258
33 Wnt signaling in triple negative breast cancer is associated with metastasis Nandini Dey, Benjamin G. Barwick, Carlos Sanchez Moreno et al. · BMC Cancer Open access 10 Nov 2013 255
34 Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development Tadahito Yasuda, Yanru Wang · Trends in cancer ReviewOpen access 9 Apr 2024 251
35 Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER Twan van den Beucken, Elizabeth Koch, Kenneth C. Chu et al. · Nature Communications Open access 29 Oct 2014 234
36 Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: A replication and extension study Brenna C. McDonald, Susan K. Conroy, Dori J. Smith et al. · Brain Behavior and Immunity Open access 21 May 2012 222
37 Human ABCG2: structure, function, and its role in multidrug resistance. Wei Mo, Jian‐Ting Zhang · PubMed Open access 2012 219
38 Cancer pain, fatigue, distress, and insomnia in cancer patients Dale Theobald · Clinical cornerstone 2004 218
39 Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism Fabrizio Pin, Rafael Barreto, Marion Everett Couch et al. · Journal of Cachexia Sarcopenia and Muscle Open access 24 Jan 2019 217
40 Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results Asim Amin, Arkadiusz Zbigniew Dudek, Theodore F. Logan et al. · Journal for ImmunoTherapy of Cancer Open access 16 Apr 2015 217
41 SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials Huilin Tang, Qi Dai, Weilong Shi et al. · Diabetologia ReviewOpen access 19 Jul 2017 212
42 Long-term toxicity of cisplatin in germ-cell tumor survivors Michal Chovanec, Mohammad I. Abu Zaid, Nasser H. Hanna et al. · Annals of Oncology Open access 13 Jul 2017 211
43 Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up Humam N. Kadara et al. · Annals of Oncology Open access 29 Sep 2016 211
44 Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro. J Brandt, Nancy R. Baird, Li Lu et al. · Journal of Clinical Investigation Open access Sep 1988 206
45 The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer Sudha S. Savant, Shruthi Sriramkumar, Heather M. O’Hagan · Cancers Open access 30 Jul 2018 205
46 Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Heather Anne Parsons et al. · Clinical Cancer Research Open access 13 Mar 2020 202
47 LSD1 and Aberrant DNA Methylation Mediate Persistence of Enteroendocrine Progenitors That Support BRAF -Mutant Colorectal Cancer Samuel A. Miller, Robert A. Policastro, Shruthi Sriramkumar et al. · Cancer Research Open access 25 May 2021 200
48 Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations Michelle J. Vaz, Stephen Y. Hwang, Ioannis Kagiampakis et al. · Cancer Cell Open access Sep 2017 199
49 Taxol Induces Caspase-10-dependent Apoptosis Soo-Jung Park, Ching-Haung Wu, John Gordon et al. · Journal of Biological Chemistry Open access 28 Sep 2004 199
50 β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids Salvatore Condello, Cynthia A. Morgan, Sarbajeet Nagdas et al. · Oncogene Open access 23 Jun 2014 199

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.